drugset / Trial / NCT05800340
Neoadjuvant Immunotherapy in Rare Mutations Localized NSCLC
Phase 2
Recruiting
30 enrolled
Guangdong Provincial People's Hospital
Shanghai Junshi Bioscience Co., Ltd. · collab
NaSingle-groupOpen-labelTreatment
Summary
Phase II, single-arm, open-label single center study that assess clinical feasibility and safety of 3 cycles neoadjuvant Toripalimab plus chemotherapy in rare mutations stage IIB-IIIB NSCLC followed by optional adjuvant treatment upon investigators' decisions.
Timeline
- Start
- 2023-04-04
- Primary completion
- 2024-12-31
- Completion
- 2026-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Carboplatin | Small molecule | — | — |
| Subject | Nab-paclitaxel | Small molecule | 135 mg/m2 | — |
| Subject | Pemetrexed | Small molecule | 500 mg/m2 | — |
| Subject | Toripalimab | Monoclonal antibody | 240 mg | — |